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Abstract
Objective—Hippocampal sclerosis of aging (HS-Aging) is a common cause of dementia in older 
adults. We tested the variability in cerebrospinal fluid (CSF) proteins associated with previously 
identified HS-Aging risk single nucleotide polymorphisms (SNPs).
Methods—Alzheimer’s Disease Neuroimaging Initiative cohort (ADNI; n=237) data, combining 
both multiplexed proteomics CSF and genotype data, were used to assess the association between 
CSF analytes and risk SNPs in four genes (SNPs): GRN (rs5848), TMEM106B (rs1990622), 
ABCC9 (rs704180), and KCNMB2 (rs9637454). For controls, non-HS-Aging SNPs in APOE 
(rs429358/rs7412) and MAPT (rs8070723) were also analyzed against Aβ1-42 and total tau CSF 
analytes.
Results—The GRN risk SNP (rs5848) status correlated with variation in CSF proteins, with the 
risk allele (T) associated with increased levels of AXL Receptor Tyrosine Kinase (AXL), TNF-
Related Apoptosis-Inducing Ligand Receptor 3 (TRAIL-R3), Vascular Cell Adhesion Molecule-1 
(VCAM-1) and clusterin (CLU) (all p<0.05 after Bonferroni correction). The TRAIL-R3 
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correlation was significant in meta-analysis with an additional dataset (p=5.05×10−5). Further, the 
rs5848 SNP status was associated with increased CSF tau protein – a marker of neurodegeneration 
(p=0.015). These data are remarkable since this GRN SNP has been found to be a risk factor for 
multiple types of dementia-related brain pathologies.
Keywords
proteomics; granulin; progranulin; Clusterin; neuroinflammation; biomarkers
INTRODUCTION
Studies of CSF analytes may provide biomarkers for dementia subtyping and also may 
provide clues about brain disease pathogenesis. These biomarker studies are all the more 
important as there are clearly many diseases in addition to Alzheimer’s disease (AD) that 
underlie the clinical syndrome of dementia. Presently, individual AD “mimics” are 
challenging in any given patient to rule in or out. Clinical studies using neuroimaging and 
CSF analyses have identified a subset of individuals with evidence of neurodegeneration but 
lacking features of AD-type amyloidogenesis according to neuroimaging or biofluid studies. 
These cases have been termed “SNAP” (suspected non-amyloid pathology) and this 
biomarker profile has been observed in approximately 1/4th of cognitively impaired 
individuals (Jack et al., 2016)
Hippocampal sclerosis of aging (HS-Aging) is among the most common of the AD mimics 
(Nelson et al., 2013, Zarow et al., 2012), and prior studies emphasize the public health 
impact of this high-morbidity SNAP-type brain condition. HS-Aging is diagnosed at autopsy 
when neuron loss and astrocytosis are observed in the hippocampal formation, out of 
proportion to AD-type plaques and tangles (Amador-Ortiz et al., 2007a, Montine et al., 
2012, Nelson et al., 2013). Unlike other diseases that share the diagnostic label of 
“hippocampal sclerosis”, HS-Aging is distinguished clinically by the advanced age of the 
individuals afflicted, and by the usual lack of either seizure disorder or frontotemporal 
dementia symptoms clinically (Amador-Ortiz et al., 2007b, Lee et al., 2008, Nelson et al., 
2011, Neumann et al., 2006, Wilson et al., 2013). Further, HS-Aging has a pathological 
biomarker: TDP-43 pathology (Amador-Ortiz et al., 2007b). HS-Aging affects up to 25% of 
the “oldest-old” (Leverenz et al., 2002, Nelson et al., 2011, Nelson et al., 2013, Zarow et al., 
2012) and is associated with substantial disease-specific cognitive impairment (Brenowitz 
W. D. et al., 2014, Nelson et al., 2010). Even at state-of-the-art research institutions, HS-
Aging tends to be misdiagnosed as AD clinically because of overlapping symptoms 
(Brenowitz et al., 2014, Nelson et al., 2011, Pao et al., 2011).
Genetic risk factors for HS-Aging have recently been characterized, comprising four specific 
gene variants that are the focus of the present study. The genes that harbor these risk-
associated variants are: GRN, TMEM106B, ABCC9, and KCNMB2. The goal of the present 
study was to test the hypothesis that the specific gene variants associated with HS-Aging 
pathology also are associated with variation in the biochemical composition of CSF.
In terms of the specific risk alleles, gene-focused studies found that SNPs were associated 
with HS-Aging that previously had been linked to frontotemporal lobar degeneration with 
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TDP-43 inclusions (FTLD-TDP), namely rs5848 (GRN) and rs1990622 (near TMEM106B) 
(Dickson D. W. et al., 2010, Murray et al., 2014, Rutherford et al., 2012, Van Langenhove et 
al., 2012). The GRN SNP was subsequently linked to other dementia-inducing disorders 
(Chang et al., 2013, Galimberti et al., 2012, Kamalainen et al., 2013, Pickering-Brown et al., 
2008, Rademakers et al., 2008). Genome-wide association studies (GWAS) using large 
datasets have implicated two genes that encode potassium channel regulators — ABCC9 
(rs704180) and KCNMB2 (rs9637454) – in HS-Aging pathology (Beecham et al., 2014, 
Nelson et al., 2014). Collectively these prior studies indicate that non-AD genes may have a 
strong impact on elderly individuals’ brain structure and function, but much remains to be 
learned about these genes’ roles in health and disease states. In contrast to AD, APOE gene 
variants are not associated with altered risk for HS-Aging (Brenowitz et al., 2014, Leverenz 
et al., 2002, Nelson et al., 2011, Pao et al., 2011, Troncoso et al., 1996), indicating that HS-
Aging is a separate disease entity from AD.
The goal of the present study was to test the hypothesis that variability in CSF analytes is 
associated with HS-Aging risk alleles in a population of older adults, many of whom are 
cognitively impaired. This study analyzed data from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) cohort and the Knight Alzheimer’s Disease Research Center (ADRC) at 
Washington University Cohort. The CSF came from lumbar punctures in patients spanning 
the clinical spectrum from normal to demented subjects (see (Ayton et al., 2015, Kang et al., 
2015)), and the average age of the research subjects when the samples were obtained was 
approximately 75 years. Our data provides support for the hypothesis that the GRN gene 
variant rs5848 is associated with neuroinflammatory brain changes in older adults.
MATERIALS AND METHODS
Subjects
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.ucla.edu). The ADNI was launched in 2003 as a public-private partnership 
(Principal Investigator Michael W. Weiner). The original ADNI study aimed to recruit 800 
adults, ages 55 to 90, to participate in the research to test whether serial magnetic resonance 
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical 
and neuropsychological assessment can be combined to measure the progression of mild 
cognitive impairment (MCI) and early AD. Participants at each site provided informed 
written consent, and protocols were approved by the respective Institutional Review Boards 
(Petersen et al., 2010). We retrieved data from the ADNI database in September 2015. CSF 
data for the present study resulted from the ADNI Biomarkers Consortium Project “Use of 
Targeted Multiplex Proteomic Strategies to Identify Novel CSF Biomarkers in AD” which 
includes quantitative data on 83 separate CSF analytes from 310 individuals after quality 
control (QC) as detailed in the ADNI CSF protocol (the pre-QC data included 159 analytes 
from a MyriadRBM multiplex assay as discussed later). We also downloaded biomarker, 
genetic, demographic and diagnosis data and required that each participant have at most one 
genotype missing, resulting in a total of 237 participants’ data being analyzed in the present 
study. (Petersen et al., 2010) This is detailed in the Genotypes and Imputation section and 
Supplemental Figure 1.
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CSF Measurements
Collection and processing of ADNI CSF samples was described in detail elsewhere (Jagust 
et al., 2009, Shaw et al., 2011)(adni.loni.ucla.edu). The Myriad RBM (Mattsson et al., 2014) 
panel of 159 CSF analytes was processed on 337 samples, including 1 from a participant 
without diagnosis and 16 replicated samples used for test/retest QC. Analytes were filtered 
for sufficient dose, precision and reproducibility and were then log-transformed to better 
approximate a normal distribution. This resulted in a total of 83 post-QC CSF analytes from 
the MyriadRBM assay. Total tau and Aβ1-42 were assayed separately (Jagust et al., 2009). 
In cases where repeated lumbar punctures were performed, only the first measurement was 
used in the present study. Descriptive measures of these analytes across the 237 individuals 
with sufficient genotype data are provided in Supplementary Table 1.
Genotyping and Imputation
The most recently generated GWAS genotyping data was acquired from the ADNI database 
September 2015. These data underwent extensive QC as part of the AD Big Data DREAM 
Challenge (Allen et al., 2016) (https://www.synapse.org/#!Synapse:syn2290704/wiki/
60828). Briefly, samples from Illumina Human610-Quad BeadChip and Illumina 
HumanOmniExpress BeadChip arrays were mapped to hg19, converted to the positive strand 
and filtered for minor allele frequency (removed MAF<0.05), SNP call rate (<0.98), sample 
call rate (<0.98), Hardy-Weinberg equilibrium (p<0.001) and relatedness. SNPs and samples 
passing QC were then pre-phased using SHAPEITv2(O’Connell et al., 2014) and imputed to 
1000 Genomes Phase 1 reference panel using default QC parameters (IMPUTE2 (Howie et 
al., 2012)).
To screen for potential ethnic outliers and protect against any potential subsequent spurious 
association, we LD pruned the GWAS data and examined principal component (PC) plots 
with 1000 Genomes data from the 5 “super populations” (African-AFR, Admixed 
American-AMR, East Asian-EAS, European-EUR and South Asian-SAS; Supplemental 
Figure 4). No outliers were discovered, and PCs were retained for adjustment in regression 
models.
Statistical Analysis
In order to discern correlations between HS-Aging genetic variants and the quantitative 
levels of CSF measurements, we performed linear regression analysis of each of the 83 post-
QC log-transformed CSF analytes separately on each of the four HS-Aging SNPs. This was 
conducted both without adjustment (i.e., marginally) and also correcting for gender, 
diagnosis, age at lumbar puncture, years of education and the first three PCs. The analysis 
was done with and without covariate adjustment as sensitivity analysis for potential 
confounding. In additional to these primary analyses, the positive controls of APOE-ε4 with 
Aβ1-42 and MAPT haplotypes with total tau were also analyzed similarly. Although a log 
transformation had already been made in the primary CSF data, any remaining violations of 
the normal distributional assumption (per a Shapiro-Wilks test for non-normality) were 
adjusted with a Box-Cox transformation.
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Since 83 individual CSF analytes were tested for association with each of the four HS-Aging 
risk SNPs, we used a Bonferroni correction and considered any result significant when p < 
1.5×10−4 (=0.05/(83*4)). We underscore that this is a conservative approach, especially 
since the Bonferroni correction explicitly assumes uncorrelated tests, although many of the 
analytes are fairly highly correlated (Supplemental Figure 2).
In addition to the primary analyses, additional analyses were performed after noting that the 
GRN SNP was significantly associated with several CSF analytes from the Myriad RBM 
panel: we investigated the relationship of this SNP with Aβ1-42 and total tau in the same 
regression framework.
Replication Analysis
A post-hoc analysis was performed that included analogous CSF and genotype data from 
286 subjects in the Knight ADRC at Washington University. All study-wide significant 
CSF/SNP relationships were meta-analyzed with Knight-ADRC data using the same 
statistical model and a inverse-variance weighted estimator to combine results.
RESULTS
Subject demographics by diagnosis for the final data set are presented in Table 1. Age of 
individuals at the time of CSF draw was approximately the same, 75 years, whether the 
patients were cognitive normal, MCI, or demented (p=0.44). Genotype SNP counts are 
presented in Table 2.
Significant Associations between CSF Analytes and HS-Aging SNPs
The Manhattan-type plot (Figure 1) displays log-transformed p-values for each CSF/SNP 
combination from regressing CSF on the SNPs’ status with adjustment for other covariates 
(gender, diagnosis, age at lumbar puncture, years of education, and the first 3 principal 
components). Marginal results, i.e., without covariate adjustment, were similar and are not 
shown. The most significant association observed was for the positive control APOE-ε4 with 
Aβ1-42 (p = 3.5×10−12). The only HS-Aging gene to reach statistical significance with any 
CSF analyte after multiple testing adjustment was GRN (rs5848_T), which revealed four 
study-wide significant correlations. Table 3 shows these results along with the corresponding 
parameter estimates from the adjusted model. For example, an additional copy of the rs5848 
T allele confers an estimated >2-fold increase (2.02 = e0.704) of AXL after adjustment for 
gender, diagnosis, age at lumbar puncture and the first three principal components. The 
distributions of AXL measures by rs5848 genotype and diagnosis are shown in Figure 2A, 
displaying the pattern of increased protein for each T allele. This is also shown for TRAIL-
R3 (Figure 2B), which is the only analyte that was study-wide significant after meta-analysis 
with the Knight ADRC data (p=5.05×10−5). No HS-Aging gene other than GRN reached 
study-wide statistical significance with the conservative Bonferroni adjustment 
(incorporating the study design of 83 analytes × 4 SNPs assessed = 332 hypothesis tests). 
Supplementary Table 2 displays regression results for the top 4 associations for each of the 
other HS-Aging genes using nominal (uncorrected) p values.
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Since the GRN rs5848_T allele was associated with CSF analytes from the RBM panel, we 
examined it in relation to tau and Aβ1-42, two canonical AD biomarkers, specifically to 
determine if the allele was associated with tau for a given level of Aβ1-42. In a model 
regressing tau level on the other covariates including Aβ1-42, the GRN risk allele showed 
association with tau levels (p=0.015). Both biomarkers were log-transformed in the model 
due to skewness. Interestingly, without the adjustment for Aβ1-42, the SNP is no longer 
nominally significantly associated with total tau levels (p=0.054). We show the residuals 
from a regression of log(tau) on Aβ1-42 and the adjustment covariates (Figure 3A) and the 
unadjusted log(tau) values (Figure 3B) against GRN genotype.
DISCUSSION
We here report that the GRN risk SNP (rs5848) was associated with variation in detected 
levels of CSF proteins previously implicated in CNS inflammation in the ADNI data set 
(Aktas et al., 2007). The same GRN risk allele was also associated with increased CSF tau 
which may indicate directly related neurodegenerative changes. We found no direct evidence 
that other putative HS-Aging risk variants are associated with variation in CSF proteins in 
these samples.
An important caveat in interpreting our results is the limited sample size (n=237 patients 
included) given the number of variables (83 analytes) being assessed. This sample size 
confers 80% power to detect an additive CSF analyte effect of 1.21 standard deviations with 
a nominal 5% level of significance, when adjusting for the 4*83=332 hypothesis tests. 
Among the additional sources of variability is the fact that the research subjects span a broad 
spectrum of clinical states from “normal” to “dementia”, which in itself probably introduces 
substantial variability related to patient activity, medication, diet, and other factors. There 
may be additional sources of variation due to possible preanalytical variables since the 
samples were collected from dozens of different clinical locations (see Methods). Moreover, 
the non-Aβ (i.e., non-AD) pathogenetic elements in large autopsy series include α-
synucleinopathy and primary age-related tauopathy (PART) which add to the phenotypic 
complexity (see for example Neltner et al. (2016)). These factors argue for caution in 
interpreting our data and heighten the likelihood of false-negative results; the study design is 
best tailored for high effect-size phenomena. Further, the CSF samples were obtained from 
relatively young individuals considering the age range of vulnerability to HS-Aging(Nelson 
et al., 2013). Another caveat relates to the basic characteristic of the ADNI cohort which is 
enriched for persons with AD risk per se. Multiple studies have found that HS-Aging tends 
to misdiagnosed as AD in the clinical setting (Brenowitz Willa D. et al., 2014, Pao et al., 
2011). However, we also note that the ADNI data set has been used productively by many 
other researchers to test hypotheses related to potential dementia biomarkers.
As far as we know this is the first study of CSF analytes in relation to HS-Aging genetic risk 
factors. The first gene variant to be linked to HS-Aging pathology, rs5848 (Rademakers et 
al., 2008) is physically located in the 3′ untranslated region of the GRN mRNA. The risk 
allele is associated with decreased plasma expression of GRN/PGRN (Dickson Dennis W. et 
al., 2010, Fenoglio et al., 2009).
Fardo et al. Page 6
Exp Gerontol. Author manuscript; available in PMC 2018 April 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Our results can be interpreted from different perspectives, reflecting how much is currently 
unknown. Whereas multiple GRN mutations cause FTLD-TDP (184–188), rs5848 is 
apparently a disease-modifying allele that alters the manifestation of multiple different 
diseases rather than affecting FTLD or HS-Aging specifically. For example, rs5848 has been 
linked to AD, Parkinson’s disease, C9ORF72 neurodegeneration, and bipolar disorder 
(Chang et al., 2013, Galimberti et al., 2012, Kamalainen et al., 2013, Pickering-Brown et al., 
2008, Rademakers et al., 2008, van Blitterswijk et al., 2014). Moreover, the SNAP profile – 
biomarker indication of a neurodegenerative process despite lack of Aβ-type 
amyloidogenesis – is linked to multiple different brain conditions. Hypothetically, one could 
have “neurodegeneration” in the CNS without tau protein in the CSF, especially in a disease 
like HS-Aging where the cell loss may occur without substantial tauopathy. The present 
study for the first time ties rs5848 related brain changes with increased CSF analytes in 
addition to CSF tau, indicating that neurodegeneration linked to TDP-43 pathology (the 
most specific pathological marker of HS-Aging) leads to increased CSF tau that can be 
detected in a complex background. A prior study reported that rs5848 status and PGRN 
levels in CSF were linked to CSF tau variance (Morenas-Rodriguez et al., 2015), whereas 
another study found that GRN mutant FTLD cases lacked increased tau in CSF (Carecchio 
et al., 2011).
Also interesting is the subset of CSF analytes that were found to be altered in association 
with rs5848 genotypes; these include AXL, TRAIL-R3, VCAM-1 and CLU. Each of these 
gene products has been the subject of extensive research, and collectively the prior studies 
appear to point towards a common theme that also is relevant to GRN itself. GRN has been 
implicated in microglial function and neuroinflammation (Cenik et al., 2012, Jian et al., 
2013), and each of the above mentioned protein products also can be linked to 
neuroinflammatory pathways. For example, CLU (clusterin, also known as apolipoprotein J) 
has been described to play a role in microglial activation and Aβ uptake (Mulder et al., 2014, 
Xie et al., 2005). Since GRN is a risk factor for FTLD-TDP, with extensive TDP-43 
pathology, as well as HS-Aging, which seems to be a different disease, it is possible that the 
GRN/PGRN protein and neuroinflammation play a contributory role in TDP-43 pathology 
per se. However, more work is required to test this hypothesis. Whether the analytes 
themselves are pathogenetic agents is another important question that remains to be 
answered.
We conclude that among subjects with CSF analyte and genotype data available in the ADNI 
cohort, the HS-Aging risk gene variants are mostly not found to be associated with CSF 
protein changes. However, the GRN risk SNP rs5848 shows some analyte variation that 
indicate high effect sizes, perhaps linked to neuroinflammatory phenotype. We now know 
that dementia has many causes and multiple pathologic comorbodities often are 
simultaneously expressed in elderly individuals. Future studies may elucidate other links 
between non-AD risk alleles and biomarkers to enable better diagnoses and to thus 
strengthen our ability to develop and test future therapeutic strategies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
GRN SNP (rs5848) genotypes correlate with variation in several CSF proteins GRN 
genotype associated with altered CSF tau protein after controlling for Aβ1-42 Related 
gene products have been linked with neuroinflammatory pathways Genetically-driven 
non-Alzheimer’s conditions have impact on aged persons’ brains
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Figure 1. 
Manhattan plot of all CSF analytes for each SNP. Linear regression results from each pair of 
log-transformed CSF analyte and SNP adjusted for gender, diagnosis, years of education, 
age at lumbar puncture and the first 3 principal components. Positive control variables are 
included with those from the primary analysis. These genes (SNPs) were tested: ABCC9 
(rs704180), APOE (rs429358/rs7412), GRN (rs5848), KCNMB2 (rs9637454), MAPT 
(rs8070723), and TMEM106B (rs1990622).
Fardo et al. Page 12
Exp Gerontol. Author manuscript; available in PMC 2018 April 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 2A. 
Violin plot of top hit CSF/SNP combination stratified by diagnosis as determined by 
statistical significance.
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Figure 2B. 
Violin plot of second hit by significance.
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Figure 3A. 
Residuals of log-transformed tau vs. GRN genotype. Residuals from a model regressing log-
transformed tau on Aβ1-42, gender, diagnosis, years of education, age at lumbar puncture 
and the first 3 principal components.
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Figure 3B. 
Unadjusted log-transformed tau vs. GRN genotype.
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Table 1
Sample demographics by diagnosis. Categorical outcomes were tested using a chi-square test. Continuous 
outcomes were tested with one-way ANOVA. An asterisk (*) denotes significance at α=0.05. Double asterisks 
(**) denote significance at α=5 × 10−8. NL = normal controls; MCI = mild cognitive impairment; AD = 
Alzheimer’s disease; LP = lumbar puncture; Aβ1-42 is the 42-residue peptide of Aβ (Naslund et al., 1994).
NL MCI AD
Sample Size 63 119 55
Female (%)* 46% 29% 45%
Age at LP 75.8 (4.8) 74.9 (7.1) 74.2 (7.6)
Years of Education 15.9 (2.7) 16.0 (3.0) 15.0 (3.1)
APOE-ε4 carrier (%)** 22% 55% 75%
Aβ1-42 (pg/mL)** 206.09 (56.89) 156.68 (48.94) 140.98 (34.40)
Total tau (pg/mL)** 69.5 (24.79) 104.37 (47.63) 125.25 (62.47)
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Table 3
Significant CSF/SNP correlations. All significant results after Bonferroni adjustment were with the GRN SNP 
(rs5848_T). The parameter estimates (beta and std. err.) reflect the log-transformations of CSF analytes and 
can be exponentiated for a fold-change interpretation after adjustment for gender, diagnosis, years of 
education, age at lumbar puncture and the first 3 principal components. AXL = AXL Receptor Tyrosine 
Kinase; TRAIL-R3 = TNF-Related Apoptosis-Inducing Ligand Receptor 3; VCAM-1 = Vascular Cell 
Adhesion Molecule-1; CLU = clusterin.
CSF Analyte beta est. std. err. Nominal p-value Bonferroni-corrected p-value
AXL 0.704 0.149 3.95E-06 0.001
TRAIL-R3 0.064 0.015 2.11E-05 0.007
VCAM-1 0.052 0.013 4.96E-05 0.016
CLU 0.062 0.016 9.19E-05 0.031
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